Skip to search formSkip to main contentSkip to account menu

carfilzomib

Known as: (2S)-N-((1S)-1-Benzyl-2-(((1S)-3-methyl-1-(((2R)-2-methyloxiran-2-yl)carbonyl)butyl)amino)-2-oxoethyl)-4-methyl-2-(((2S)-2-((morpholin-4-ylacetyl)amino)-4-phenylbutanoyl)amino)pentanamide 
An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

Kyprolis
NCIt Antineoplastic Agent TerminologyPR-171Proteasome Inhibitors [MoA]carfilzomib 60 MG Injection [Kyprolis]

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and…
INTRODUCTION. Bortezomib, lenalidomide and dexamethasone (VRd) is considered a standard of care combination therapy for newly… 
2019
2019
Randomized phase 3 study of carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible , NDMM patients Running title : KMP vs VMP for newly diagnosed multiple myeloma
250 Text: 4000/4000 Figures/tables: 5/4 (total = 9) References: 32/100 Blood First Edition Paper, prepublished online February 28… 
2017
2017
Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): An open-label, phase 1b study.
8000Background: DARA in combination with established standard of care regimens prolongs PFS, deepens responses, and demonstrates… 
2016
2016
Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed…
Introduction In a phase 1/2 study designed to assess KRd w/o ASCT, KRd provided a high rate of stringent complete response (sCR… 
2015
2015
Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer.
Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies. Currently, there is no standard or effective… 
2015
2015
Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
Research has shown that proteasome inhibitors (e.g., carfilzomib), immunomodulatory agents (e.g., lenalidomide), histone… 
Review
2014
Review
2014
The emerging role of carfilzomib combination therapy in the management of multiple myeloma
Carfilzomib is a proteasome inhibitor that selectively and irreversibly binds to its target, resulting in sustained inhibition… 
Review
2013
Review
2013
Diagnosis and therapy of multiple myeloma
Many advances in the treatment of multiple myeloma have been made due to the use of transplantation and the introduction of novel… 
2011
2011
Elucidation of the α-keto-aldehyde binding mechanism: a lead structure motif for proteasome inhibition.
Lead role: The role of peptidyl alpha-keto aldehydes as proteasome inhibitors is well established, yet their molecular binding… 
2011
2011
Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)
Abstract 631 [][1] Introduction: In relapsed and/or refractory MM, the combination of carfilzomib (CFZ) with lenalidomide (Len… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)